IVBIY
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metab… Read more
IVBIY (IVBIY) - Total Liabilities
Latest total liabilities as of June 2025: $9.17 Billion USD
Based on the latest financial reports, IVBIY (IVBIY) has total liabilities worth $9.17 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IVBIY - Total Liabilities Trend (2020–2024)
This chart illustrates how IVBIY's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IVBIY Competitors by Total Liabilities
The table below lists competitors of IVBIY ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Broadridge Financial Solutions Inc
NYSE:BR
|
USA | $5.76 Billion |
|
Henkel AG & Co. KGaA
PINK:HENOF
|
USA | $12.67 Billion |
|
Weichai Power Co. Ltd
F:WI4
|
Germany | €239.03 Billion |
|
US Foods Holding Corp
NYSE:USFD
|
USA | $9.64 Billion |
|
BOE Technology Group Co Ltd
SHE:000725
|
China | CN¥225.82 Billion |
|
Aristocrat Leisure Limited
PINK:ARLUF
|
USA | $2.54 Billion |
|
Novozymes A/S B
PINK:NVZMF
|
USA | $5.66 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down IVBIY's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IVBIY's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IVBIY (2020–2024)
The table below shows the annual total liabilities of IVBIY from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.48 Billion | +4.75% |
| 2023-12-31 | $8.10 Billion | +18.09% |
| 2022-12-31 | $6.86 Billion | +15.99% |
| 2021-12-31 | $5.91 Billion | +93.55% |
| 2020-12-31 | $3.06 Billion | -- |